Results 131 to 140 of about 37,430 (216)

Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa‐Based Regimen in Newly Diagnosed Primary CNS Lymphoma

International Journal of Cancer, Volume 159, Issue 6, Page 1499-1509, 15 September 2026.
Primary central nervous system diffuse large B‐cell lymphoma (PCNS‐DLBCL) lacks an optimal first‐line induction strategy, particularly for older patients and those ineligible for intensive consolidation. In this retrospective cohort of 36 newly diagnosed patients, the rituximab + methotrexate + thiotepa (RMT) regimen as first‐line induction achieved ...
Haotian Wang, Jia Li, Luming Cao, Ying Zhang, Xin Wan, Xingtong Wang, Yangzhi Zhao, Zhaoxia Li, Chengqian Chen, Yang Song, Ou Bai   +10 more
wiley   +1 more source

Lenalidomide-Associated Rhabdomyolysis Progressing to Bilateral Compartment Syndrome and Permanent Foot Drop. [PDF]

Case Rep Oncol Med
Iyer K, Chetan S, Arkala A, Siegel CS, Gadi B, Popu C, Oke V, Cadiz BS.   +7 more
europepmc   +1 more source

IMiD-based monotherapy for maintenance of remission in primary CNS lymphoma: a single-center experience. [PDF]

Blood Neoplasia
Randall MP, Tsang M, Gee J, Yung C, Rubenstein JL.   +4 more
europepmc   +1 more source

Lenalidomide Exposure and <i>TP53</i>-Mutated Myelodysplastic Syndromes/Neoplasms. [PDF]

Curr Oncol
Katamesh B, Shallis RM.
europepmc   +1 more source

Economic advantage of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: A cost-per-responder evaluation. [PDF]

J Manag Care Spec Pharm
Gautam S, Morrison L, Thompson-Leduc P, Samandur A, Macomson B, Khare V, Yin X, Medhekar R.   +7 more
europepmc   +1 more source

Persistence to Multiple Myeloma Treatments Given at First Relapse-Results From the Australian Real-World OPTIMISE Study. [PDF]

EJHaem
Buescher F, Su S, Waterhouse B, Pinto C.
europepmc   +1 more source

Cardiovascular disease and amyloidosis in phase III multiple myeloma trials: a systematic review of eligibility, screening and event reporting. [PDF]

Open Heart
Henriques Peck O, McCoubrey A, Snowden JA, Wechalekar A, Travers J, Lees JS, Petrie MC, Lang NN.   +7 more
europepmc   +1 more source

Correction: Frontline daratumumab, lenalidomide, and dexamethasone in patients older than 80 years with newly diagnosed multiple myeloma: treatment durability, infectious complications, and nutritional vulnerability. [PDF]

Blood Res
Horigome Y, Ehata K, Tadera N, Hayama K, Kamata H, Suzuki T, Miyazaki K.   +6 more
europepmc   +1 more source

Case Report: From complete remission to severe anemia: pure red cell aplasia emerged after VRd regimen in multiple myeloma. [PDF]

Front Oncol
Zhang X, Hu T, Dai H, Yuan H.
europepmc   +1 more source

Multiple Myeloma and Renal Health: Navigating Selected Clinical Complexities. [PDF]

Cureus
Hussain A, Moniot JL, Sumaya M, Hughes DM.   +3 more
europepmc   +1 more source